Results - Announcements
Suven Life Sciences Ltd share price softened by 0.14% to Rs 275.75 after the company's net profit fell 16.20% to Rs 106.94 crore, while revenue from operations plunged by 66.39% to Rs 1.2 crore in Q3FY26 over Q2FY26.
The market capitalization of Healthcare Research, Analytics & Technology industry group stocks on BSE stood at Rs 43081.67 crore, gaining 7.69%. It has marginally improved by 4.28% over last one week and edged lower by 0.39% in last one month while the market capitalization of Suven Life Sciences Ltd has improved by 6.84% and 13.34% in the same period respectively.
Profit before tax (PBT) of Suven Life Sciences Ltd stood at Rs 106.94 crore in Q3 FY26, jumping 38.33% year-on-year, and crashing by 16.20% quarter-on-quarter. EBITDA came in at Rs 118 crore, rallying 40.81% YoY and tanking 15.98% sequentially.
Total expenses reduced by 17.22% to Rs 114.42 crore in Q3FY26 over Q3FY25. During the quarter, employee benefits expense was at Rs 7.19 crore, dipping slightly 1.24% YoY.
For the TTM ended FY26, revenue from operations grew marginally by 6.76% to Rs 7.11 crore, while net profit surged by 71.91% to Rs 276.34 crore, compared to previous TTM. EBITDA tumbled by 17789% to Rs 298.44 crore, and PBT witnessed a strong rise of 71.91% to Rs 276.34 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 301.79 crore in FY26, as against Rs 154.1 crore in FY25.
Suven Life Sciences Ltd rallied 43.43% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.80% during the same period.